BiotechTube
Home/Novo Nordisk/Doug Langa
DL

Doug Langa

Executive Vice President, North America Operations & President of Novo Nordisk Inc.

Novo Nordisk

Therapeutic Areas

DiabetesObesityRare Blood & Endocrine DisordersCardiovascular DiseaseChronic Kidney Disease

Novo Nordisk Pipeline

DrugIndicationPhase
Wegovy HD (semaglutide 7.2mg)ObesityApproved
Awiqli®Type 2 DiabetesApproved
UBT251 (Triple Agonist)Type 2 DiabetesPhase 2
CagriSema (Subcutaneous)Obesity, Type 2 DiabetesPhase 3
Oral CagriSemaObesity, Type 2 DiabetesPhase 2
Subcutaneous ZenagamtideObesity, DiabetesPhase 2
Amycretin (Subcutaneous)ObesityPhase 2
Oral AmycretinObesityPhase 2

Leadership Team at Novo Nordisk

LF
Lars Fruergaard Jørgensen
President and Chief Executive Officer
KM
Karsten Munk Knudsen
Executive Vice President & Chief Financial Officer
MS
Marcus Schindler
EVP Research & Early Development, Chief Scientific Officer
MH
Martin Holst Lange
Executive Vice President, Development
HW
Henrik Wulff
Executive Vice President, Product Supply, Quality & IT
CS
Camilla Sylvest
Executive Vice President, Commercial Strategy & Corporate Affairs
MD
Mike Doustdar
Executive Vice President, International Operations
LH
Ludovic Helfgott
Executive Vice President, Rare Disease
DM
David Moore
Executive Vice President, Corporate Development
View full Novo Nordisk profile